Concepedia

Efficacy and safety of crizotinib in ALK-positive systemic anaplastic large-cell lymphoma in children, adolescents, and adult patients: results of the French AcSé-crizotinib trial

Laurence Brugières, Nathalie Cozic, Roch Houot, Charlotte Rigaud, David Sibon, Julia Arfi‐Rouche, Pierre Bories, Anne‐Ségolène Cottereau, Alain Delmer, Stéphane Ducassou,

European Journal of Cancer · 2023 · 27 citations · 22 references

DOIFull text

Open access

Concepts

References

22

Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification

Bruce D. Cheson, Richard I. Fisher, Sally F. Barrington et al. · Journal of Clinical Oncology · 2014 · 5.6K citations · Full text

, , +17

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

Steven M. Horwitz, Owen A. O’Connor, Barbara Pro et al. · The Lancet · 2018 · 726 citations · Full text

, , +12

Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study

Yaël P. Mossé, Megan S. Lim, Stephan D. Voss et al. · The Lancet Oncology · 2013 · 701 citations · Full text

, , +11

CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib

Daniel B. Costa, Susumu Kobayashi, Shuchi S. Pandya et al. · Journal of Clinical Oncology · 2011 · 590 citations · Full text

, , +17

Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children’s Oncology Group Study

Yaël P. Mossé, Stephan D. Voss, Megan S. Lim et al. · Journal of Clinical Oncology · 2017 · 403 citations · Full text

, , +15